• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What's New in Anticoagulation.

作者信息

Razavi Joanna Esther Molina, Safavi-Naeini Payam, Razavi Mehdi

出版信息

Tex Heart Inst J. 2016 Oct 1;43(5):419-421. doi: 10.14503/THIJ-16-5920. eCollection 2016 Oct.

DOI:10.14503/THIJ-16-5920
PMID:27777526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5067036/
Abstract
摘要

相似文献

1
What's New in Anticoagulation.抗凝治疗的新进展。
Tex Heart Inst J. 2016 Oct 1;43(5):419-421. doi: 10.14503/THIJ-16-5920. eCollection 2016 Oct.
2
Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future.非瓣膜性心房颤动口服抗凝剂的使用不足：过去、现在与未来
Tex Heart Inst J. 2016 Aug 1;43(4):287-90. doi: 10.14503/THIJ-16-5785. eCollection 2016 Aug.
3
Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation.老年房颤患者抗凝治疗的禁忌证及新型抗凝剂的适用情况
Cardiovasc Ther. 2015 Aug;33(4):177-83. doi: 10.1111/1755-5922.12129.
4
Effectively Initiating and Maintaining Anticoagulation in Patients With Atrial Fibrillation.在心房颤动患者中有效启动和维持抗凝治疗
Circulation. 2019 Apr 9;139(15):1763-1765. doi: 10.1161/CIRCULATIONAHA.118.037564.
5
Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.非维生素K拮抗剂口服抗凝药时代之前心房颤动患者的抗栓治疗：心房颤动患者长期口服抗栓治疗全球注册研究（GLORIA-AF）第一阶段队列研究
Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073. Epub 2016 Jun 21.
6
Which oral anticoagulant for atrial fibrillation.用于心房颤动的口服抗凝剂该如何选择。
Med Lett Drugs Ther. 2016 Apr 11;58(1492):45-6.
7
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.直接口服抗凝剂在心房颤动合并心脏瓣膜病变患者中的应用。
J Am Heart Assoc. 2016 Feb 18;5(2):e002776. doi: 10.1161/JAHA.115.002776.
8
Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.新型口服抗凝剂在非瓣膜性心房颤动卒中预防中的应用的实际考虑。
Cardiovasc Ther. 2014 Apr;32(2):74-81. doi: 10.1111/1755-5922.12048.
9
Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.心房颤动患者口服抗凝治疗的依从性。聚焦于非维生素K拮抗剂口服抗凝药。
Thromb Haemost. 2017 Jan 26;117(2):209-218. doi: 10.1160/TH16-10-0757. Epub 2016 Nov 10.
10
Anticoagulation of elderly patients at high risk for falls with atrial fibrillation.对有跌倒高风险的老年房颤患者进行抗凝治疗。
Med Lett Drugs Ther. 2017 Feb 27;59(1515):35-36.

引用本文的文献

1
Medical and Device Therapy for Stroke Prevention in Patients With Atrial Fibrillation.心房颤动患者预防中风的药物和器械治疗
Tex Heart Inst J. 2021 Sep 1;48(4). doi: 10.14503/THIJ-21-7549.

本文引用的文献

1
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence.依度沙班预防和治疗血栓栓塞的最新进展：基于当前证据的临床应用
Adv Hematol. 2015;2015:920361. doi: 10.1155/2015/920361. Epub 2015 Aug 16.
2
Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management.心房颤动中的新型抗凝剂：监测、逆转及围手术期管理
Biomed Res Int. 2015;2015:424031. doi: 10.1155/2015/424031. Epub 2015 Jul 2.
3
Target-specific oral anticoagulants: should we switch from warfarin?靶向性口服抗凝剂：我们应该停用华法林吗？
Tex Heart Inst J. 2015 Jun 1;42(3):229-33. doi: 10.14503/THIJ-15-5065. eCollection 2015 Jun.
4
Idarucizumab for Dabigatran Reversal.达比加群酯逆转剂依达鲁珠单抗。
N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
5
Heart disease and stroke statistics--2015 update: a report from the American Heart Association.《2015年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17.
6
Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting.围手术期非维生素K拮抗剂口服抗凝剂的管理
Biomed Res Int. 2014;2014:385014. doi: 10.1155/2014/385014. Epub 2014 Sep 3.
7
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南：美国心脏病学会/美国心脏协会实践指南工作组及心律学会的报告
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28.
8
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.肾功能损害对口服直接 Xa 因子抑制剂利伐沙班的药代动力学、药效学和安全性的影响。
Br J Clin Pharmacol. 2010 Nov;70(5):703-12. doi: 10.1111/j.1365-2125.2010.03753.x.
9
Apixaban metabolism and pharmacokinetics after oral administration to humans.阿哌沙班口服给药后在人体内的代谢及药代动力学。
Drug Metab Dispos. 2009 Jan;37(1):74-81. doi: 10.1124/dmd.108.023143. Epub 2008 Oct 2.
10
New oral Xa and IIa inhibitors: updates on clinical trial results.
J Thromb Thrombolysis. 2008 Feb;25(1):52-60. doi: 10.1007/s11239-007-0108-7. Epub 2007 Oct 27.